The Diagenode agreement is the first in what BD expects to be a string of similar deals with molecular diagnostics developers in order to expand the number of tests that can run on the BD Max.
The partnership combines Seegene's Dual Priming Oligo multiplex PCR technology with Akonni's TruArray gel-drop microarray technology.
The companies will co-develop seven assays for pathogens associated with respiratory, enteric, and central nervous system diseases.
The firms will combine their technologies to develop molecular diagnostic tests for infectious pathogens that cause respiratory diseases.
Celera will manufacture the multiplex assay, which will be the next-generation version of Qiagen's ResPlex II assay for detecting respiratory pathogens.
The company will use an SBIR and an STTR grant to develop POC tests for HIV and respiratory diseases.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.